ViSci Visual Sciences Ltd.

ViSci Visual Sciences Ltd. is at the forefront of medical equipment manufacturing, dedicated to innovative solutions in the treatment of glaucoma. ViSci’s groundbreaking Eye-D technology employs a sub-conjunctival implant designed for the sustained release of Latanaprost, effectively eliminating the need for daily eye drops, a significant advantage for many patients. The VS-101 implant, developed by ViSci, represents a significant advancement in glaucoma management. The company is located at 2234 Street, Kiryat Atidim, Tel Aviv, 6158101, IL.

ViSci Visual Sciences Ltd. is poised to make a substantial impact on the global glaucoma drug market, projected to exceed $10 billion by 2026. The company's solutions address the critical need for reduced treatment burden while maintaining efficacy and economic viability. ViSci’s unique implanter facilitates a simple and quick in-office procedure, offering a superior alternative to traditional eye drop treatments.

ViSci is committed to advancing its technology and expanding its reach to improve patient outcomes worldwide. More detailed information about ViSci Visual Sciences Ltd. and its ongoing projects will be available soon, thanks to the support of the company’s management. We invite the manager of ViSci Visual Sciences Ltd. to create a customized and exclusive company showcase and product listing on our platform to further highlight their innovative work.